Publications

Articles

Dong, M., & Gagnon, M.-A. (2025). Unveiling chemical industry secrets: Insights gleaned from scientific literatures that examine internal chemical corporate documents-A scoping review. PloS One, 20(1), e0310116. https://doi.org/10.1371/journal.pone.0310116

Grundy, Q. 2025. Delivering the script: The educational activities of medical device industry representatives as a knowledge management strategy. Social Science & Medicine, 384, 118565. https://doi.org/10.1016/j.socscimed.2025.118565
Gagnon, M.-A. 2024. Commentary: Which Principles for a National Strategy for Rare Diseases? Healthcare Policy 19 (4): 27–31. https://www.longwoods.com/content/27353/commentary-which-principles-should-apply-for-a-national-strategy-on-rare-diseases-
García Carrillo M, Gagnon M.-A. and Blaustein M. Editorial: Current priorities in health research agendas: tensions between public and commercial interests in prioritizing biomedical, social, and environmental aspects of health. Frontiers in Medicine. March 2024 Vol. 11 :1391982. doi: 10.3389/fmed.2024.1391982. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1391982/full
Lexchin J, Dong BM, Ramanathan A, Gagnon MA. Phase IV drug trials with a Canadian site: a comparison of industry-funded and non-industry-funded trials. Int J Health Policy Manag. March 2024; Vol. 13:8239. doi:10.34172/ijhpm.2024.8239. https://www.ijhpm.com/article_4576.html
M.-A. Gagnon & M.-H. Bacon. Le temps est venu d’améliorer la transparence à l’Agence de réglementation de la lutte antiparasitaire de Santé Canada. CMAJ February 2024 196 (6), E-206-E208 (Translation of Gagnon and Bacon 2023),. https://www.cmaj.ca/content/196/6/E206
Gagnon MA, Dong M. What did the scientific literature learn from internal company documents in the pharmaceutical industry? A scoping review. Cochrane Evidence Synthesis and Methods. 2023;1(3):e12011: https://onlinelibrary.wiley.com/doi/full/10.1002/cesm.12011
Gagnon, M.-A. & Bacon, M.-H. (2023). Time to Improve Transparency at Health Canada’s Pest Management Regulatory Agency. CMAJ, 195(46), E1583–E1584. https://doi.org/10.1503/cmaj.231089

Grundy, Q., Quanbury, A., Hart, D., Chaudhry, S., Tavangar, F., Lexchin, J., Gagnon, M.-A., & Tadrous, M. (2023). Prevalence and Nature of Manufacturer-Sponsored Patient Support Programs for Prescription Drugs in Canada: A Cross-Sectional Study. CMAJ, 195(46), E1565–E1576. https://doi.org/10.1503/cmaj.230841

Bensussan, H., Durand, C., & Rikap, C. (2023). 100 years of Corporate Planning. From Industrial Capitalism to Intellectual Monopoly Capitalism through the lenses of the Harvard Business Review (1922-2021). Université de Genève. https://archive-ouverte.unige.ch/unige:171107

Gagnon, M.-A. (2023). Commentary: Reconsidering Pharmaceutical Research and Development Investments. Healthcare Policy, 18(3). https://www.longwoods.com/content/27037/healthcare-policy/commentary-reconsidering-pharmaceutical-research-and-development-investments
Bacon, M.-H., Vandelac, L., Gagnon, M.-A., & Parent, L. (2023). Poisoning Regulation, Research, Health, and the Environment: The Glyphosate-Based Herbicides Case in Canada. Toxics, 11(2), Article 2. https://doi.org/10.3390/toxics11020121
García Carrillo M., Testoni F., Gagnon M.-A., Rikap C., Blaustein M.. Academic dependency: the influence of the prevailing international biomedical research agenda on Argentina’s CONICET. Heliyon. 2022 Nov 1;8(11):e11481: https://t.co/je5ozgGvqH
Testoni F.E., García Carrillo M., Gagnon M.-A., Rikap C., Blaustein M. Whose shoulders is health research standing on? Determining the key actors and contents of the prevailing biomedical research agenda. PLOS ONE. 2021 Apr 7;16(4): e0249661: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249661
Lexchin J., Bero L.A., Davis C., Gagnon M.-A. Achieving greater independence from commercial influence in research. BMJ. 2021 Mar 9;372:n370 : https://www.bmj.com/content/372/bmj.n370
Gagnon M.-A. La Canada face à l’iniquité vaccinale globale : se situer du mauvais côté de l’histoire. Rev Interventions Économiques / Papers in Political Economy [Internet]. 2021 Nov 1 [cited 2022 Nov 25]; (Hors-série. Transformations). Available from: https://journals.openedition.org/interventionseconomiques/14794
Gagnon, M.-A. (2021). Understanding the Battle for Universal Pharmacare in Canada; Comment on “Universal Pharmacare in Canada.” International Journal of Health Policy and Management, 10(3), 168–171. https://doi.org/10.34172/ijhpm.2020.40
Gagnon, M.-A. (2019). Co-pay cards in Canada: Improving choice or institutionalizing bribes? CMAJ, 191(45), E1235–E1236. https://doi.org/10.1503/cmaj.191447
Charbonneau, M., & Gagnon, M.-A. (2018). Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs. Health Policy, 122(12), 1295–1301. https://doi.org/10.1016/j.healthpol.2018.08.006
Lexchin J., Kohler J.C., Gagnon M.-A., Crombie J., Thacker P., Shnier A.. Combating corruption in the pharmaceutical arena. Indian J Med Ethics. 2018 Sep;3(3):234–9: https://ijme.in/articles/combating-corruption-in-the-pharmaceutical-arena/

Book Chapters

Gagnon, MA, 2024. “The anatomy of Big Pharma”. In Primrose D, Loeppky Rand Chang R. (eds) The Routledge Handbook of the Political Economy of Health and Healthcare. London and New York: Routledge: pp.245-258. https://www.taylorfrancis.com/chapters/edit/10.4324/9781003017110-23/anatomy-big-pharma-marc-andr%C3%A9-gagnon?context=ubx&refId=d01bc120-9b80-4c0a-aa95-1ca753bf6be6
Gagnon M.-A. Combatting Corruption in the Pharmaceutical Sector. In: Faintuch J, Faintuch S, editors. Integrity of Scientific Research: Fraud, Misconduct and Fake News in the Academic, Medical and Social Environment [Internet]. Cham: Springer International Publishing; 2022: p. 477–86. Available from: https://doi.org/10.1007/978-3-030-99680-2_47
Gagnon M.-A. Ghost management as a central feature of accumulation in corporate capitalism : The case of the global pharmaceutical sector. In: Marlène Benquet, Théo Bourgeron, editors. Accumulating Capital Today. London and New York: Routledge; 2021. https://www.taylorfrancis.com/chapters/edit/10.4324/9781003089513-15/ghost-management-central-feature-accumulation-corporate-capitalism-marc-andr%C3%A9-gagnon

E-Books

Blaustein, M., Gagnon, M.-A., Garcia Carrillo, M., eds. (2024). Current priorities in health research agendas: Tensions between public and commercial interests in prioritizing biomedical, social, and environmental aspects of health. Lausanne: Frontiers Media SA. https://www.frontiersin.org/research-topics/48714/current-priorities-in-health-research-agendas-tensions-between-public-and-commercial-interests-in-prioritizing-biomedical-social-and-environmental-aspects-of-health/articles

Policy Briefs & Technical Reports

Marc-André Gagnon Pharmacare and Access to Medicines in Canada: Is Bill C-64 a Step in the Right Direction? Perspectives Journal. November 7, 2024. https://perspectivesjournal.ca/pharmacare-bill-c64/
Marc-André Gagnon and Quinn Grundy. Preferred Provider Networks in Employer-Sponsored Drug Insurance Sector; Some necessary considerations. Submission to Ontario Ministry of Finance. October 21 2024. https://carleton.ca/ghostmanagement/wp-content/uploads/Brief-PPN-Ontario_QG-FInal.pdf
Marc-André Gagnon. Pharmacare and Access to Medicines in Canada; A Policy Brief. Submission to Canadian Senate Standing Committee on Social Affairs, Science and Technology. September 13 2024. https://carleton.ca/ghostmanagement/wp-content/uploads/PMRA-Submission-Revised-16082023-1-1.pdf
Marc-André Gagnon, Marie-Hélène Bacon and Louise Vandelac. Reinforcing regulation and transparency at Health Canada’s PMRA; some necessary considerations. Submission to Health Canada. August 1 2023. https://carleton.ca/ghostmanagement/wp-content/uploads/PMRA-Submission-Revised-16082023-.pdf
Marc-André Gagnon. Mergers and Acquisitions in the Pharmaceutical Sector; Some Necessary Considerations. Submission to US Federal Trade Commission Pharmaceutical Task Force, Project No. P212900, June 25 2021. https://carleton.ca/ghostmanagement/wp-content/uploads/Submission-on-MAs-in-the-pharmaceutical-sector.pdf
Marc-André Gagnon, Anil Varughese et Nahya Awada. Developing a National Strategy for Rare Diseases in Canada; Some Necessary Considerations. Submitted to Health Canada, March 26 2021. https://carleton.ca/ghostmanagement/wp-content/uploads/Submission-on-rare-disease.pdf
Marc-André Gagnon et Joel Lexchin. Soumission quant à la prise en considération d’une nouvelle capacité de biofabrication pour le Canada; De la nécessité de repenser nos manières de faire. Présenté à Innovation, Sciences et Développement Économique Canada, 12 mars 2021. https://carleton.ca/ghostmanagement/wp-content/uploads/Memoir-about-Biomanufacturing-in-Canada-3.pdf

Op-Eds & Commentaries

Marc-André Gagnon. « Penser l’assurance médicaments pour l’intérêt de la population » La Presse. 6 décembre 2023 : https://www.lapresse.ca/dialogue/opinions/2023-12-06/replique/penser-l-assurance-medicaments-pour-l-interet-de-la-population.php
Rehn, T. (2023, November 27). Nouveaux OGM, ou quand les consultations publiques deviennent une mascarade. Le Devoir. https://www.ledevoir.com/opinion/idees/802714/idees-nouveaux-ogm-ou-quand-consultations-publiques-deviennent-mascarade [not affiliated with the GM Research Group]

Marc-André Gagnon. “Quelles mains sont aux commandes de la recherche médicale?” Le Devoir, 25 juin 2021 : https://www.ledevoir.com/opinion/idees/613608/etude-des-interets-commerciaux-lies-de-pres-a-la-recherche-medicale
Marc-André Gagnon. “La suspension des brevets sur les vaccins; Faire partie de la solution”. Options Politiques, 27 mai 2021 : https://policyoptions.irpp.org/magazines/may-2021/la-suspension-des-brevets-sur-les-vaccins-faire-partie-de-la-solution/
Joel Lexchin, Barbara Mintzes, Kelly Holloway, Marc-André Gagnon. “Guidelines governing Canadian doctors’ relationships with pharma companies under review”. The Conversation, November 12 2020: https://theconversation.com/guidelines-governing-canadian-doctors-relationships-with-pharma-companies-under-review-149519
Joel Lexchin, Barbara Mintzes,Lisa Bero, MA Gagnon, Quinn Grundy(2020). “Canada’s COVID-19 Vaccine Task Force needs better transparency about potential conflicts of interest”. The Conversation. October 8 2020: https://theconversation.com/canadas-covid-19-vaccine-task-force-needs-better-transparency-about-potential-conflicts-of-interest-147323
Marc-André Gagnon and Louise Vandelac, 2020. “Privilégier l’industrie pharmaceutique au détriment de la recherche publique?” Le Devoir. 3 septembre 2020: https://www.ledevoir.com/opinion/idees/585254/sante-privilegier-l-industrie-pharmaceutique-au-detriment-de-la-recherche-publique

News Articles

Crowe, K. (2023, March 23). Pharma lobby paid StatCan for reports then used in industry PR push. The Breach. Retrieved March 27, 2023, from https://breachmedia.ca/pharma-lobby-paid-statistics-canada-reports-used-industry-pr-push/.

Lectures

Gagnon, M.-A. (2023, March). Une pilule difficile à avaler. Coeur des sciences. Montreal; Quebec. Retrieved March 27, 2023, from
https://tv.uqam.ca/conference-penurie-medicaments-une-pilule-difficile-avaler.

Documentaries/TV Broadcasts

Gignac, B. (Director). (2023). Prix des médicaments: Le bon dosage. In L’enquête McSween. Télé-Québec. https://video.telequebec.tv/player/45410/stream?assetType=episodes [not affiliated with the GM Research group]

Podcast Appearances

McClelland, J., & Gagnon, M.-A. (November 13, 2024). The Continuing Battle for Universal Pharmacare with Marc-André Gagnon [Broadcast]. https://perspectivesjournal.ca/the-continuing-battle-for-universal-pharmacare-with-marc-andre-gagnon/

Share: Twitter, Facebook
Short URL: https://carleton.ca/ghostmanagement/?p=51